US 12,005,124

Application 18/492,894 · Granted Jun 11, 2024

Muscle targeting complexes and uses thereof for treating dystrophinopathies

Estimated expiration

August 2, 2039

12y 257d remaining

Confidence: high
High: no high-severity warning was raised, and any terminal disclaimer was resolved to the patents it references.
Earliest effective filing
Aug 2, 2019
+ 20 years
Aug 2, 2039
PTA +0d
Aug 2, 2039
TD cap (US 11,168,141)
Aug 2, 2039
Final
Aug 2, 2039

This calculation includes patent term adjustment (PTA) under 35 U.S.C. §154(b). Patent term extension (PTE) under 35 U.S.C. §156 (for FDA-regulated products) is not included. Terminal disclaimers can affect PTA (In re Cellect, LLC).

Calculation details

Base term

Filing date
October 24, 2023
Earliest effective filing
August 2, 2019
Issue date
June 11, 2024
PTA
0 days
Base expiry (before PTA)
August 2, 2039

August 2, 2019 + 20 years = August 2, 2039

  • Continuation of application 18/181,623, filed Mar 10, 2023, issued as US 11,833,217
  • Continuation of application 17/930,522, filed Sep 8, 2022, issued as US 11,633,496
  • Continuation of application 17/751,875, filed May 24, 2022, issued as US 11,497,815
  • Continuation of application 17/580,844, filed Jan 21, 2022, issued as US 11,369,689
  • Continuation of application 17/501,066, filed Oct 14, 2021, issued as US 11,248,056
  • Continuation of application 17/205,151, filed Mar 18, 2021, issued as US 11,168,141
  • Continuation of application 17/265,024, filed Feb 1, 2021
  • National stage entry of application PCTUS2019044949, filed Aug 2, 2019
  • National stage entry of application PCTUS2019044949, filed Aug 2, 2019
  • Continuation of application 17/265,024, filed Feb 1, 2021
  • National stage entry of application PCTUS2019044949, filed Aug 2, 2019
  • Continuation of application 17/205,151, filed Mar 18, 2021, issued as US 11,168,141
  • Continuation of application 17/265,024, filed Feb 1, 2021
  • National stage entry of application PCTUS2019044949, filed Aug 2, 2019
  • Continuation of application 17/501,066, filed Oct 14, 2021, issued as US 11,248,056
  • Continuation of application 17/205,151, filed Mar 18, 2021, issued as US 11,168,141
  • Continuation of application 17/265,024, filed Feb 1, 2021
  • National stage entry of application PCTUS2019044949, filed Aug 2, 2019
  • Continuation of application 17/580,844, filed Jan 21, 2022, issued as US 11,369,689
  • Continuation of application 17/501,066, filed Oct 14, 2021, issued as US 11,248,056
  • Continuation of application 17/205,151, filed Mar 18, 2021, issued as US 11,168,141
  • Continuation of application 17/265,024, filed Feb 1, 2021
  • National stage entry of application PCTUS2019044949, filed Aug 2, 2019
  • Continuation of application 17/751,875, filed May 24, 2022, issued as US 11,497,815
  • Continuation of application 17/580,844, filed Jan 21, 2022, issued as US 11,369,689
  • Continuation of application 17/501,066, filed Oct 14, 2021, issued as US 11,248,056
  • Continuation of application 17/205,151, filed Mar 18, 2021, issued as US 11,168,141
  • Continuation of application 17/265,024, filed Feb 1, 2021
  • National stage entry of application PCTUS2019044949, filed Aug 2, 2019
  • Continuation of application 17/930,522, filed Sep 8, 2022, issued as US 11,633,496
  • Continuation of application 17/751,875, filed May 24, 2022, issued as US 11,497,815
  • Continuation of application 17/580,844, filed Jan 21, 2022, issued as US 11,369,689
  • Continuation of application 17/501,066, filed Oct 14, 2021, issued as US 11,248,056
  • Continuation of application 17/205,151, filed Mar 18, 2021, issued as US 11,168,141
  • Continuation of application 17/265,024, filed Feb 1, 2021
  • National stage entry of application PCTUS2019044949, filed Aug 2, 2019
  • PRO62/714,031 — Provisional — not used for base term
  • PRO62/855,766 — Provisional — not used for base term
  • PRO62/855,766 — Provisional — not used for base term
  • PRO62/714,031 — Provisional — not used for base term
  • PRO62/855,766 — Provisional — not used for base term
  • PRO62/714,031 — Provisional — not used for base term
  • PRO62/855,766 — Provisional — not used for base term
  • PRO62/714,031 — Provisional — not used for base term
  • PRO62/855,766 — Provisional — not used for base term
  • PRO62/714,031 — Provisional — not used for base term
  • PRO62/855,766 — Provisional — not used for base term
  • PRO62/714,031 — Provisional — not used for base term
  • PRO62/855,766 — Provisional — not used for base term
  • PRO62/714,031 — Provisional — not used for base term
  • PRO62/855,766 — Provisional — not used for base term
  • PRO62/714,031 — Provisional — not used for base term
  • PRO62/855,766 — Provisional — not used for base term
  • PRO62/714,031 — Provisional — not used for base term

Terminal disclaimers

TD approved1 approved, 2 filed

TD caps expiration to August 2, 2039 (earliest expiring referenced patent: US 11,168,141)

  • US 11,168,141· Application 17/205,151Capping patent

    Muscle targeting complexes and uses thereof for treating dystrophinopathies

    Filing date
    Mar 18, 2021
    Earliest effective filing
    Aug 2, 2019
    Issue date
    Nov 9, 2021
    PTA
    0 days
    Calculated expiration
    Aug 2, 2039

    Continuation of 17/265,024, filed Feb 1, 2021

    National stage entry of PCTUS2019044949, filed Aug 2, 2019

    National stage entry of PCTUS2019044949, filed Aug 2, 2019

    Aug 2, 2019 + 20y = Aug 2, 2039

  • US 11,248,056· Application 17/501,066

    Muscle targeting complexes and uses thereof for treating dystrophinopathies

    Filing date
    Oct 14, 2021
    Earliest effective filing
    Aug 2, 2019
    Issue date
    Feb 15, 2022
    PTA
    0 days
    Calculated expiration
    Aug 2, 2039

    Continuation of 17/205,151, filed Mar 18, 2021, issued as US 11,168,141

    Continuation of 17/265,024, filed Feb 1, 2021

    National stage entry of PCTUS2019044949, filed Aug 2, 2019

    National stage entry of PCTUS2019044949, filed Aug 2, 2019

    Continuation of 17/265,024, filed Feb 1, 2021

    National stage entry of PCTUS2019044949, filed Aug 2, 2019

    Aug 2, 2019 + 20y = Aug 2, 2039

  • US 11,369,689· Application 17/580,844

    Muscle targeting complexes and uses thereof for treating dystrophinopathies

    Filing date
    Jan 21, 2022
    Earliest effective filing
    Aug 2, 2019
    Issue date
    Jun 28, 2022
    PTA
    0 days
    Calculated expiration
    Aug 2, 2039

    Continuation of 17/501,066, filed Oct 14, 2021, issued as US 11,248,056

    Continuation of 17/205,151, filed Mar 18, 2021, issued as US 11,168,141

    Continuation of 17/265,024, filed Feb 1, 2021

    National stage entry of PCTUS2019044949, filed Aug 2, 2019

    National stage entry of PCTUS2019044949, filed Aug 2, 2019

    Continuation of 17/265,024, filed Feb 1, 2021

    National stage entry of PCTUS2019044949, filed Aug 2, 2019

    Continuation of 17/205,151, filed Mar 18, 2021, issued as US 11,168,141

    Continuation of 17/265,024, filed Feb 1, 2021

    National stage entry of PCTUS2019044949, filed Aug 2, 2019

    Aug 2, 2019 + 20y = Aug 2, 2039

  • US 11,497,815· Application 17/751,875

    Muscle targeting complexes and uses thereof for treating dystrophinopathies

    Filing date
    May 24, 2022
    Earliest effective filing
    Aug 2, 2019
    Issue date
    Nov 15, 2022
    PTA
    0 days
    Calculated expiration
    Aug 2, 2039

    Continuation of 17/580,844, filed Jan 21, 2022, issued as US 11,369,689

    Continuation of 17/501,066, filed Oct 14, 2021, issued as US 11,248,056

    Continuation of 17/205,151, filed Mar 18, 2021, issued as US 11,168,141

    Continuation of 17/265,024, filed Feb 1, 2021

    National stage entry of PCTUS2019044949, filed Aug 2, 2019

    National stage entry of PCTUS2019044949, filed Aug 2, 2019

    Continuation of 17/265,024, filed Feb 1, 2021

    National stage entry of PCTUS2019044949, filed Aug 2, 2019

    Continuation of 17/205,151, filed Mar 18, 2021, issued as US 11,168,141

    Continuation of 17/265,024, filed Feb 1, 2021

    National stage entry of PCTUS2019044949, filed Aug 2, 2019

    Continuation of 17/501,066, filed Oct 14, 2021, issued as US 11,248,056

    Continuation of 17/205,151, filed Mar 18, 2021, issued as US 11,168,141

    Continuation of 17/265,024, filed Feb 1, 2021

    National stage entry of PCTUS2019044949, filed Aug 2, 2019

    Aug 2, 2019 + 20y = Aug 2, 2039

  • US 11,633,496· Application 17/930,522

    Muscle targeting complexes and uses thereof for treating dystrophinopathies

    Filing date
    Sep 8, 2022
    Earliest effective filing
    Aug 2, 2019
    Issue date
    Apr 25, 2023
    PTA
    0 days
    Calculated expiration
    Aug 2, 2039

    Continuation of 17/751,875, filed May 24, 2022, issued as US 11,497,815

    Continuation of 17/580,844, filed Jan 21, 2022, issued as US 11,369,689

    Continuation of 17/501,066, filed Oct 14, 2021, issued as US 11,248,056

    Continuation of 17/205,151, filed Mar 18, 2021, issued as US 11,168,141

    Continuation of 17/265,024, filed Feb 1, 2021

    National stage entry of PCTUS2019044949, filed Aug 2, 2019

    National stage entry of PCTUS2019044949, filed Aug 2, 2019

    Continuation of 17/265,024, filed Feb 1, 2021

    National stage entry of PCTUS2019044949, filed Aug 2, 2019

    Continuation of 17/205,151, filed Mar 18, 2021, issued as US 11,168,141

    Continuation of 17/265,024, filed Feb 1, 2021

    National stage entry of PCTUS2019044949, filed Aug 2, 2019

    Continuation of 17/501,066, filed Oct 14, 2021, issued as US 11,248,056

    Continuation of 17/205,151, filed Mar 18, 2021, issued as US 11,168,141

    Continuation of 17/265,024, filed Feb 1, 2021

    National stage entry of PCTUS2019044949, filed Aug 2, 2019

    Continuation of 17/580,844, filed Jan 21, 2022, issued as US 11,369,689

    Continuation of 17/501,066, filed Oct 14, 2021, issued as US 11,248,056

    Continuation of 17/205,151, filed Mar 18, 2021, issued as US 11,168,141

    Continuation of 17/265,024, filed Feb 1, 2021

    National stage entry of PCTUS2019044949, filed Aug 2, 2019

    Aug 2, 2019 + 20y = Aug 2, 2039

Notes (1)

  • [TD_REFS_TRUNCATED] Found 19 TD references; resolving first 5 only

Patent term extension under 35 U.S.C. §156, which can apply to certain drug, biologic, animal drug and medical device patents, is not included in this calculation. How PTE is calculated

You have the date. Your AI can have the file.

Application 18/492,894 · US 12,005,124

PatentReply compiles the prosecution history behind US 12,005,124: the claims as filed and as allowed, every Office Action and response, and the cited references, with each answer pointing back to the filed passage.

One new published application a month is free. The first compile takes a few minutes.

Strategy and filing changes require your approval.

How PatentReply handles an Office Action response →

Permanent link

www.patentreply.ai/tools/patent-expiration/US12005124

Data sourced from public USPTO records. This tool provides informational estimates and should not be relied upon as legal advice. Always verify patent expiration dates independently, especially where patent term extension, terminal disclaimers, or unusual continuity issues may apply.